RK Asset Management LLC Has $7.12 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

RK Asset Management LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,989 shares of the biopharmaceutical company’s stock after purchasing an additional 896 shares during the quarter. Regeneron Pharmaceuticals comprises about 5.8% of RK Asset Management LLC’s investment portfolio, making the stock its 6th largest holding. RK Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $7,115,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of REGN. Rakuten Securities Inc. raised its position in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares in the last quarter. Sachetta LLC lifted its stake in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the last quarter. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $26,000. Fairfield Financial Advisors LTD acquired a new position in Regeneron Pharmaceuticals in the third quarter worth approximately $37,000. Finally, Ashton Thomas Private Wealth LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at $39,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on REGN. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Barclays reduced their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Piper Sandler lowered their price objective on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Evercore ISI reduced their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Finally, Wells Fargo & Company lowered their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,052.90.

Regeneron Pharmaceuticals Stock Up 0.4 %

Shares of NASDAQ REGN traded up $2.96 during midday trading on Friday, reaching $718.15. The company’s stock had a trading volume of 557,944 shares, compared to its average volume of 518,522. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $693.00 and a fifty-two week high of $1,211.20. The stock has a 50 day simple moving average of $772.73 and a 200-day simple moving average of $976.16. The stock has a market capitalization of $78.92 billion, a price-to-earnings ratio of 17.77, a PEG ratio of 2.19 and a beta of 0.10. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.